Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

NCT04466150 · clinicaltrials.gov ↗

PHASE4

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Relapsing Multiple Sclerosis
Clinically Isolated Syndrome

Interventions

DRUG: Ocrelizumab

Sponsor

University of California, San Francisco

Collaborators

[object Object]
[object Object]